enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA approves groundbreaking treatment for advanced melanoma - AOL

   www.aol.com/fda-approves-groundbreaking...

   The Food and Drug Administration on Friday approved a new cancer therapy that could one day transform the way a majority of aggressive and advanced tumors are treated.. The treatment, called ...

3. Vemurafenib - Wikipedia

   en.wikipedia.org/wiki/Vemurafenib

   Vemurafenib was approved in the United States for the treatment of late-stage melanoma in August 2011, [23] making it the first drug designed using fragment-based lead discovery to gain regulatory approval. [24] Vemurafenib was approved for use in Canada in February 2012. [25]

4. The ‘Carter effect’: How the former president gave cancer ...

   www.aol.com/news/carter-effect-former-president...

   Since Carter’s diagnosis, at least 15 new treatments for stage 4 melanoma have been approved, said Dr. Michael Davies, chair of the department of melanoma and medical oncology at MD Anderson ...

5. Nivolumab/relatlimab - Wikipedia

   en.wikipedia.org/wiki/Nivolumab/relatlimab

   Nivolumab/relatlimab, sold under the brand name Opdualag, is a fixed-dose combination medication use to treat melanoma. [10] It contains nivolumab, a programmed death receptor-1 (PD-1) blocking antibody, and relatlimab, a lymphocyte activation gene-3 (LAG-3) blocking antibody. [10] It is given by intravenous infusion. [10]

6. FDA approves new therapy for hard-to-treat metastatic melanoma

   www.aol.com/news/fda-approves-therapy-hard-treat...

   On Friday, the US Food and Drug Administration approved a new, first-of-its-kind therapy that could help patients with metastatic melanoma, a rare but deadly form of skin cancer.

7. MEK inhibitor - Wikipedia

   en.wikipedia.org/wiki/MEK_inhibitor

   Cobimetinib or XL518, approved by US FDA in Nov 2015 for use in combination with vemurafenib (Zelboraf(R)), for treatment of advanced melanoma with a BRAF V600E or V600K mutation. Selumetinib , had a phase 2 clinical trial for non-small cell lung cancer (NSCLC) which demonstrated an improvement in PFS, [ 5 ] and is now in phase III development ...